Medicines sues generic drugmakers over Angiomax patent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The Medicines Company has filed lawsuits against Teva Parenteral Medicines, Pliva Hrvatska and APP Pharmaceuticals over Angiomax (bivalirudin) patent infringement.

The Parsippany, N.J.-based company filed the lawsuit with U.S. District Court for the District of Delaware, alleging patent infringement based on abbreviated new drug applications seeking FDA approval to market and sell generic versions of Angiomax product prior to expiration of U.S. Patent No. 7,582,727 (the '727 patent).

Each lawsuit alleges infringement of the '727 patent, which was issued to Medicines on Sept. 1, and scheduled to expire in March of 2010. The company could have obtained a four-year extension had they not missed the deadline to file for extended patent exclusivity by merely a day.